トポイソメラーゼ阻害薬
“Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis”. J. Med. Chem. 48 (15): 4803–14. (2005). doi:10.1021/jm050076b. PMID 16033260.
“Development of a validated immunofluorescence assay for yH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity”. Clin. Cancer Res. 16 (22): 5447–57. (Nov 2010). doi:10.1158/1078-0432.ccr-09-3076. PMC 2982895. PMID 20924131. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982895/.
“Design, synthesis, and evaluation of dibenzo[c,h[1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents”]. J. Med. Chem. 53 (24): 8716–26. (Dec 2010). doi:10.1021/jm101048k. PMC 3064471.
Chem. 48 (7): 2336–45. (Apr 2005). doi:10.1021/jm049146p. PMID 15801827.
Teicher BA (2008). “Next generation topoisomerase I inhibitors: rationale and biomarker strategies”. Biochem. Pharmacol. 75 (6): 1262–71. doi:10.1016/j.bcp.2007.10.016. PMID 18061144.
“Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives”. Bioorg. Med. Chem. 16 (6): 3153–62. (2008). doi:10.1016/j.bmc.2007.12.028. PMID 18180162.
“Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription”. Nat. Cell Biol. 11 (11): 1315–24. (Nov 2009). doi:10.1038/ncb1984. PMC 2912930. PMID 19838172. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912930/.